Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib

INTRODUCTION: Angiogenesis and EGFR signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways may prolong progression-free survival in first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Breast Cancer
Autores principales: Symonds, L, Linden, H, Gadi, V, Korde, L, Rodler, E, Gralow, J, Redman, M, Baker, K, Wu, V, Jenkins, I, Kurland, B, Garrison, M, Smith, J, Anderson, J, Van Haelst, C, Specht, J
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440867/
https://ncbi.nlm.nih.gov/pubmed/30737173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2018.12.008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares